CPT code 81270 – JAK2 V617F billing and coverage guide

Key takeaways

CPT Code 81270 reports JAK2 V617F variant analysis and sits in Tier 1 of the AMA’s molecular pathology codes.

Medicare coverage is local, with LCD L35000 in Wellpoint Federal states and a MolDX LCD in MolDX states.

Supported diagnoses center on polycythemia vera (D45), essential thrombocythemia (D47.3) and primary myelofibrosis (D47.4), and symptom-only ICD-10 codes routinely trigger denial.

Labs billing Medicare in MolDX jurisdictions (Palmetto GBA, Noridian, WPS and CGS) need a DEX Z-code on the claim before 81270 is paid.

Pabau, the practice management platform we build, submits CMS-1500/837P claims through Claim.MD and tracks their status.

CPT Code 81270: quick-reference summary

CPT Code 81270 reports a lab test that looks for the JAK2 V617F variant in peripheral blood or bone marrow. It is a Tier 1 molecular pathology code, paid by Medicare under the Clinical Laboratory Fee Schedule (CLFS). Coverage depends on the Medicare Administrative Contractor (MAC) that processes the claim.

Official code description and what it covers

CPT Code 81270 covers detection of the JAK2 V617F point mutation, whatever analytical platform the lab uses. Under the AMA’s CPT code set, each Tier 1 molecular pathology code reports analysis of one named gene or variant. 81270 is the Tier 1 code for the JAK2 V617F variant.

The code covers the test itself, not a separate interpretation. Every acceptable methodology bills as a single unit of 81270.

• Allele-specific PCR (ASO-PCR): the most common method for detecting JAK2 V617F, with high sensitivity and wide use in clinical labs
• Pyrosequencing: quantitative variant detection, useful for monitoring allele burden over time
• Next-generation sequencing (NGS): V617F may be detected on a targeted NGS panel. In that case, 81270 may apply only if the panel does not map to 81450, 81451 or 81455.
• Specimen types: peripheral blood (EDTA) and bone marrow aspirate are both acceptable, and the specimen type does not change the CPT code

CPT Code 81270 does not cover other JAK2 variants. JAK2 targeted sequence analysis (for example, exons 12 and 13) is reported under CPT 81279. Exon 12 mutations turn up in a small subset of polycythemia vera cases that test V617F-negative. Billing 81270 for an exon 12 assay is a coding error.

Clinical indications and supporting ICD-10 codes

CPT Code 81270 fits when a patient’s clinical picture suggests a myeloproliferative neoplasm (MPN), and the ordering physician documents the reason for testing. Covered indications center on BCR-ABL negative myeloproliferative disease, led by polycythemia vera, coded D45. The exact covered list sits in your MAC’s LCD: L35000 in Wellpoint Federal states, or the MolDX LCD elsewhere.

CPT Code 81270 is not appropriate for routine oncology screening or family history-based genetic counseling. Payers deny claims where the ICD-10 code reflects only a symptom, such as R71.8 (other abnormality of red blood cells). Clinical documentation must support a confirmed or suspected MPN diagnosis.

Medicare coverage rules: local LCDs and MolDX

Medicare coverage for CPT Code 81270 is local, so the rules depend on your MAC. Each contractor’s policy is listed in the CMS Medicare Coverage Database. Wellpoint Federal, formerly National Government Services (NGS), covers JAK2 V617F testing under LCD L35000 (Molecular Pathology Procedures). That LCD applies in Illinois, Minnesota, Wisconsin, Connecticut, New York, Maine, Massachusetts, New Hampshire, Rhode Island and Vermont.

MolDX contractors use their own LCD, MolDX: Non-Next Generation Sequencing Tests for the Diagnosis of BCR-ABL Negative Myeloproliferative Neoplasms (L39923 in JE, for example). It replaced the older Genetic Testing for BCR-ABL Negative Myeloproliferative Disease LCDs, such as L36180 (JE) and L36186 (JF), in August 2025. Novitas and First Coast claims follow those contractors’ own local policies.

MolDX vs non-MolDX jurisdictions

MolDX is a MAC program run by Palmetto GBA, with Noridian, WPS and CGS participating. In MolDX jurisdictions, labs must register JAK2 tests in the DEX Z-code registry before Medicare will pay the claim. Non-MolDX jurisdictions apply their local policy without the registry step.

Labs that skip DEX Z-code registration in a MolDX jurisdiction will see 81270 denials, even when the indication and ICD-10 pairing are correct. Registration is free, but the lab must submit a technology assessment through the MolDX portal at dexzcodes.com before billing.

2026 Medicare fee schedule and payment for 81270

CPT Code 81270 is paid under the Clinical Laboratory Fee Schedule (CLFS), not the Physician Fee Schedule. CMS publishes the CLFS national limitation amount each year, and it caps Medicare payment. Check the current 2026 rate on the CMS Clinical Laboratory Fee Schedule page, since CLFS rates can shift between years.

• Technical component only: 81270 has no professional component split, so modifiers -26 and -TC do not apply. Billing -26 causes a claim error. Billing -TC is redundant, and some payers reject it outright.
• Commercial payer rates: vary by contract. Most payers don’t post commercial rates publicly, so labs verify them through payer contracts or fee schedule request letters.
• No geographic modifier: CLFS payments are national rates. Unlike Physician Fee Schedule codes, there is no geographic practice cost index (GPCI) adjustment for 81270.

How CPT Code 81270 differs from related JAK2 and MPN codes

CPT Code 81270 is V617F-specific, so billing it for any other JAK2 analysis is incorrect code assignment. The table below covers the codes most often confused with 81270.

Billing 81270 and 81279 on the same date of service is permissible when both analyses are independently ordered and documented. Append modifier 59 only if a payer or NCCI edit bundles the pair, and check the current NCCI table before you do.

Prior authorization and payer requirements

Traditional Medicare does not require prior authorization for CPT Code 81270. Commercial managed care and Medicaid HMO plans often do.

• Traditional Medicare (Parts A and B): no prior auth required. Medical necessity is reviewed retrospectively against the covered indications in your MAC’s LCD.
• Medicare Advantage plans: individual plan policies vary. Some MA plans layer prior auth requirements on top of traditional Medicare coverage rules. Verify with each MA plan before ordering.
• Commercial managed care: most require prior authorization. Plans typically ask for the ordering physician’s NPI, clinical notes on MPN suspicion or confirmation, CBC results showing elevated counts, and the supporting ICD-10 codes.
• Medicaid FFS vs Medicaid HMO: fee-for-service Medicaid policies vary by state. Medicaid HMO plans typically require prior auth and may add network or prior authorization restrictions on molecular pathology.

Documentation requirements for 81270 claims

Insufficient documentation causes most 81270 denials, even when the clinical indication is present. Medical billing compliance rules in L35000 and the MolDX LCD specify what must be in the record when the claim is submitted.

What the ordering physician record must contain

• The clinical reason for ordering JAK2 testing, such as symptoms or a suspected MPN, stated explicitly rather than implied by the ICD-10 code
• Ordering provider’s NPI (individual, not group NPI) as it appears on the claim
• Date the order was placed, matching or preceding the specimen collection date
• Prior lab results supporting the clinical decision (CBC showing erythrocytosis, thrombocytosis, or leukoerythrocytosis as applicable)

What the performing lab record must contain

• Validated assay name and specific methodology used (for example, allele-specific PCR or pyrosequencing)
• Specimen type and date of collection
• Analytical result with the detected allele burden percentage if quantitative
• Interpreting pathologist’s or clinical laboratory geneticist’s attestation
• DEX Z-code (MolDX jurisdictions only), which must appear on the claim if the lab is registered in MolDX

Submitting a clean claim for CPT Code 81270 requires both record sets to be complete before billing. Post-payment audits of molecular pathology claims look first at the ordering provider’s documentation.

Common claim denial reasons and how to prevent them

CPT Code 81270 claims sit where genetic testing policy, ICD-10 specificity and, in MolDX states, a separate registry meet. Good denial management for JAK2 claims starts with six recurring denial patterns. Four of them can be caught at order entry, before the specimen is even run.

For appeals on non-covered ICD-10 denials, attach the ordering physician’s clinical note directly. On molecular pathology claims, the medical billing denial codes to watch are CARC 50 (not medically necessary) and CARC 4 (inconsistent with modifier used). CARC 50 is usually addressable with clinical documentation on first-level appeal, and CARC 4 with a corrected modifier.

Billing CPT Code 81270 with modifiers

CPT Code 81270 is a technical component-only code, which settles the two modifier questions coders ask most often.

• Modifier -26 (professional component): does not apply. 81270 has no professional component, so appending -26 causes a claim error or denial.
• Modifier -TC (technical component): does not apply. The code is inherently technical-component only, so adding -TC is redundant and may trigger a payer reject.
• Modifier 59 (distinct procedural service): use it only if a payer or NCCI edit bundles 81270 and 81279 on the same date of service. Check the current NCCI table, and append it to the code the edit names.
• Modifier 91 (repeat clinical diagnostic laboratory test): applies only when a second test is medically necessary on the same day to get a new result. It does not apply to a rerun after failed QC or a specimen problem.
• Modifier QW (CLIA-waived test): not applicable. JAK2 V617F analysis is high-complexity testing under CLIA, so no waiver modifier applies.

Reviewing superbill practices for molecular pathology helps labs capture modifier decisions at order entry, rather than correcting them after a denial. The superbill or lab order form should state that -26 and -TC never apply to 81270.

How claims management software reduces 81270 denials

Most of the checks above happen by hand today. A biller confirms the diagnosis code, the MAC and the payer’s authorization rule, then keys the claim into a clearinghouse portal. Each handoff is another chance for a wrong ICD-10 code or a missing Z-code to reach the payer.

Pabau, the practice management platform we build, keeps the order, the diagnosis and the clinical note in one patient record. Its claims management software pulls that existing record data into a pre-filled claim. Claim.MD, our claim submission integration, sends CMS-1500/837P claims and tracks their status.

Eligibility checks through Claim.MD confirm active coverage before the specimen is collected. The result is fewer 81270 claims coming back for data the practice already had on file.

Submit and track 81270 claims in one place

Pabau keeps the order, diagnosis and clinical note in one record, then submits 837P claims through Claim.MD and tracks their status. Fewer 81270 claims come back for missing data.

Book a demo

Conclusion

CPT Code 81270 denials are almost always preventable, because the code itself is well defined. The errors come from the decisions around it: the ICD-10 pairing, MolDX registration in a MolDX jurisdiction, and modifiers on a technical-component-only code.

Start with your MAC. Once you know whether L35000 or the MolDX LCD governs your Medicare claims, the covered diagnosis list and the registry step follow from it. Build those rules into order entry, and the denials left over are the ones a clinical note can win on appeal. Book a demo to see how Pabau keeps molecular pathology claims complete from order to submission.

Continue your research

Need to understand how clearinghouse submission works for lab claims? Medical claims clearinghouse guide explains how electronic claim routing reduces denial rates for high-complexity lab codes.

Working through a claim denial on a molecular pathology code? Electronic remittance advice (ERA) explained covers how to read 835 remittances and identify CARC denial codes for appeals.

Want to understand how insurance eligibility verification affects lab billing? Insurance eligibility verification guide walks through the eligibility checks that confirm active coverage before specimen collection.

Coding the diagnosis behind the test? ICD-10 code D45 covers polycythemia vera, the primary indication for JAK2 V617F testing.

Running a molecular test with no specific CPT code? CPT code 81479 explains how to bill unlisted molecular pathology procedures.

Frequently asked questions